Furthermore, the SAL-MODULE study, a phase I trial, extended this combination strategy to patients with CBF-AML and FLT3-mutated AML, demonstrating its broader applicability and clinical feasibility. This evidence concerns the gene FLT3 and acute myeloid leukemia.